Keyword: Mylan

Theravance logo

46. Yupelri

In November, Theravance and Mylan’s Yupelri became the first once-daily, nebulized bronchodilator for chronic obstructive pulmonary disorder.

10. GlaxoSmithKline

GlaxoSmithKline has one of the lowest R&D budgets in percentage of revenue terms of its peers; although its research budget was slightly up on 2015, this is still markedly down from the around £4 billion it was spending in 2012-13.